Skip to content
Biodatica
Start free

Novartis Pharmaceuticals

Cheonan Si, Chungcheongnam-do

OncologyPhase IIIListed · NVS

This company trades under its own ticker, so it sits outside Biodatica’s pre-ticker window. The record stays here because its filings are real, but the feed leaves listed companies out unless you ask for them.

Compare Sign in to watch

What changed

Phase II trial registered: EPIK-P4: A Phase II Single-arm Study to Assess the Efficacy, Safety and Pharmacokinetics of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum (PROS)

1w agoTrial registeredJul 8, 2026Source filing (opens the source filing in a new tab)

Momentum

100no change

Momentum 100 out of 100, unchanged since the last recompute.

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase III

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Trial

    Study registered

    Jun 30, 2026

    Chronic Myeloid Leukemia · NOT_YET_RECRUITING · sponsor: Novartis Pharmaceuticals · A Study of Asciminib Safety and Efficacy in Young Adults With Chronic Myeloid Leukemia in the Gulf Region

    ClinicalTrials.gov · NCT07681258 (opens the source filing in a new tab)

  2. Trial

    PHASE2 registered

    Oct 9, 2025

    PIK3CA-related Overgrowth Spectrum (PROS) · RECRUITING · sponsor: Novartis Pharmaceuticals · EPIK-P4: A Phase II Single-arm Study to Assess the Efficacy, Safety and Pharmacokinetics of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum (PROS)

    ClinicalTrials.gov · NCT06997588 (opens the source filing in a new tab)

  3. Trial

    Study registered

    Mar 12, 2025

    B-Cell Acute Lymphoblastic Leukemia, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma · RECRUITING · sponsor: Novartis Pharmaceuticals · Long-term Follow up Local Registry Study of Kymriah in South Korea

    ClinicalTrials.gov · NCT06785818 (opens the source filing in a new tab)

  4. Trial

    PHASE3 registered

    Aug 13, 2024

    Hematologic Malignancy, Solid Tumor, Advanced Malignancies · RECRUITING · sponsor: Novartis Pharmaceuticals · An Extension Study for Patients Previously Enrolled in Studies With Pelabresib

    ClinicalTrials.gov · NCT06401356 (opens the source filing in a new tab)

  5. Trial

    Study registered

    Jan 15, 2024

    PIK3CA-Related Overgrowth Spectrum · COMPLETED · sponsor: Novartis Pharmaceuticals · A Study of the Epidemiology and Hospital Management of Patients With PROS in France

    ClinicalTrials.gov · NCT07222423 (opens the source filing in a new tab)

  6. Trial

    Study registered

    Jul 19, 2023

    Chronic Myeloid Leukemia · RECRUITING · sponsor: Novartis Pharmaceuticals · Asciminib RMP Study

    ClinicalTrials.gov · NCT05943522 (opens the source filing in a new tab)

  7. Trial

    Study registered

    Jun 21, 2023

    Hormone Receptor Positive HER2 Negative Breast Cancer With a PIK3CA Mutation · TERMINATED · sponsor: Novartis Pharmaceuticals · A NIS of Alpelisib in Combination With Fulvestrant in Postmenopausal Women, and Men, With HR+,HER2- , Locally Advanced or Metastatic Breast Cancer With a PIK3CA Mutation, After Disease Progression Following Endocrine Therapy as Monotherapy, in the Real-world Setting

    ClinicalTrials.gov · NCT04967248 (opens the source filing in a new tab)

  8. Trial

    Study registered

    Apr 7, 2023

    Graft-versus-Host Disease · RECRUITING · sponsor: Novartis Pharmaceuticals · A PMS of Jakavi® in Patients With Steroid-Refractory Graft-versus-Host Disease (SR-GvHD) in Korea

    ClinicalTrials.gov · NCT05621733 (opens the source filing in a new tab)

  9. Trial

    Study registered

    Jan 12, 2023

    Chronic Rhinosinusitis With Nasal Polyps · COMPLETED · sponsor: Novartis Pharmaceuticals · Regulatory Post-Marketing Surveillance of Xolair® for Chronic Rhinosinusitis With Nasal Polyps

    ClinicalTrials.gov · NCT05626257 (opens the source filing in a new tab)

  10. Trial

    Study registered

    Jul 5, 2022

    Myeloid Leukemia, Chronic · COMPLETED · sponsor: Novartis Pharmaceuticals · A Study of Real-world Treatment and Burden of Chronic Myeloid Leukemia Patients in Japan

    ClinicalTrials.gov · NCT07150793 (opens the source filing in a new tab)

  11. Trial

    Study registered

    Jun 29, 2022

    Breast Cancer · RECRUITING · sponsor: Novartis Pharmaceuticals · A Post Marketing Surveillance on Piqray in Korea

    ClinicalTrials.gov · NCT05293470 (opens the source filing in a new tab)

  12. Trial

    Study registered

    Feb 28, 2022

    Breast Cancer · COMPLETED · sponsor: Novartis Pharmaceuticals · Survey Among Healthcare Professionals Treating Patients With Metastatic Breast Cancer in Selected European Countries to Evaluate Their Knowledge on Management of Hyperglycemia When Using Alpelisib

    ClinicalTrials.gov · NCT05073120 (opens the source filing in a new tab)

  13. Trial

    Study registered

    Oct 27, 2021

    Breast Cancer · COMPLETED · sponsor: Novartis Pharmaceuticals · Study of PIK3CA Mutations and Effectiveness and Tolerability Outcomes of Alpelisib in Real-world

    ClinicalTrials.gov · NCT05022342 (opens the source filing in a new tab)

  14. Trial

    Study registered

    Jul 27, 2021

    Breast Cancer · COMPLETED · sponsor: Novartis Pharmaceuticals · A Prospective Observational Study to Describe Clinical Outcomes, Treatment Patterns, Patients Characteristics Among Patients With HR+/HER2- Advanced BC Initiating Treatment With Risarg®, Piqray®, Endocrine Therapy or Chemotherapy in Routine Clinical Practice in Russia

    ClinicalTrials.gov · NCT04943497 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources